During the last session, Benitec Biopharma Inc. (NASDAQ:BNTC)’s traded shares were 3.03 million, with the beta value of the company hitting 1.14. At the end of the trading day, the stock’s price was $0.24, reflecting an intraday gain of 13.39% or $0.03. The 52-week high for the BNTC share is $2.10, that puts it down -775.0 from that peak though still a striking 45.83% gain since the share price plummeted to a 52-week low of $0.13. The company’s market capitalization is $6.31M, and the average intraday trading volume over the past 10 days was 0.45 million shares, and the average trade volume was 289.20K shares over the past three months.
Benitec Biopharma Inc. (NASDAQ:BNTC) trade information
Benitec Biopharma Inc. (BNTC) registered a 13.39% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 13.39% in intraday trading to $0.24 this Thursday, 05/25/23, hitting a weekly high. The stock’s 5-day price performance is 19.90%, and it has moved by 18.40% in 30 days. Based on these gigs, the overall price performance for the year is -74.04%. The short interest in Benitec Biopharma Inc. (NASDAQ:BNTC) is 0.34 million shares and it means that shorts have 0.94 day(s) to cover.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
While earnings are projected to return 31.10% in 2023.
BNTC Dividends
Benitec Biopharma Inc. is due to release its next quarterly earnings on May 15. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Benitec Biopharma Inc. (NASDAQ:BNTC)’s Major holders
Benitec Biopharma Inc. insiders own 7.93% of total outstanding shares while institutional holders control 52.09%, with the float percentage being 56.58%. Franklin Resources, Inc. is the largest shareholder of the company, while 29 institutions own stock in it. As of Mar 30, 2023, the company held over 10.0 million shares (or 35.74% of all shares), a total value of $2.36 million in shares.
The next largest institutional holding, with 0.8 million shares, is of Empery Asset Management, LP’s that is approximately 2.85% of outstanding shares. At the market price on Sep 29, 2022, these shares were valued at $0.19 million.
Also, the Mutual Funds coming in first place with the largest holdings of Benitec Biopharma Inc. (BNTC) shares are Franklin Strategic Series-Franklin Biotechnology Discove and Vanguard Extended Market Index Fund. Data provided on Jan 30, 2023 indicates that Franklin Strategic Series-Franklin Biotechnology Discove owns about 6.2 million shares. This amounts to just over 22.17 percent of the company’s overall shares, with a $1.47 million market value. The same data shows that the other fund manager holds slightly less at 74773.0, or about 0.27% of the stock, which is worth about $17661.0.
